Tag Archives: orphan

Hot Investor Mandate 3: Strategic Investment Firm of Large Pharma Invests in Early and Late Stage Therapeutics & Drug-Device Combinations, Especially Interested in Orphan and Rare Diseases

5 Jul

A strategic investment firm of a large global pharmaceutical makes investments ranging from $5 million to $30 million, acting either as a sole investor or within a syndicate. The firm is open to considering therapeutic opportunities globally, but only if the company is pursuing a market opportunity in the USA and is in dialogue with the US FDA.

The firm invests in therapeutics, and in this sector the firm is interested in both early and late stage assets. The firm will consider any type of therapeutic technology (including small molecules, large molecules and gene therapies), and has a strong preference for investing in orphan drugs and other niche disease areas. It is preferred that indications have validated clinical endpoints and can be studied using small trials. Indications that require large clinical trials, including as cardiovascular diseases, CNS diseases and primary care indications (such as influenza) will not be considered. Drug-device combinations will also be considered.

The firm prefers to work with companies who have opened dialogue with the FDA. The firm considers a high-quality management team to be a significant requirement of their investment criteria. It is preferred that assets can reach the marketplace 3-5 years post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Orphan Drug Investors Share Their Insights at RESI San Diego

11 May

By Lucy Parkinson, Director of Research, LSN

Orphan diseases present a unique opportunity for a biotech investor; faster development, market exclusivity and the possibility of delivering a cure to patients with no current treatment options. However, these small markets also present unique challenges in development and strategy.

At RESI San Diego, five experienced investors who specialize in rare disease opportunities will explain their strategies in the sector. These investors will explore how they identify potential in a rare disease therapeutic, and how they turn tiny markets into significant ROI.

Moderated by Ken Kengatharan, General Partner, Atheneos Capital, panelists include:

Hot Life Science Investor Mandate 3: Single Family Office Looking to Catalyze Larger Funding Rounds

3 Jul

A Family Office based in the Eastern United States is looking to make equity investments into early stage companies in the life science space that can be used to catalyze larger rounds from other institutional investors. The firm’s typical allocation size is between $200,000-$500,000. The firm is currently looking for companies around the US. The firm is looking to make approximately 4 investments over the next 6-9 months.

The firm is currently looking for companies developing therapeutics and is open to both small molecules and biologics. The firm is generally open to all indications within these areas including orphan indications. The firm is willing to invest in both pre-clinical and clinical stage companies with a preference for those with some in-human data.

The firm is looking for privately held companies with experienced management teams. The firm’s main mission is to help companies catalyze larger rounds by helping attract other more large scale investors. The firm looks to take a board seat on a case by case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

%d bloggers like this: